Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC (PRTC)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
02/23SANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/08FTSE slides after BOE meeting as pound pops higher
RE
02/08REGENERON PHARMACEUTICALS : Collaborations Drive Revenue Increase at Regeneron -..
DJ
02/07GlaxoSmithKline sees light at end of Advair tunnel
RE
02/07Sanofi's return to profit growth this year slower than hoped
RE
02/06GILEAD SCIENCES : Reports Quarterly Loss Driven by Tax Charge -- Earnings Review
DJ
01/30Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
01/29Sanofi to Buy Ablynx for $4.85 Billion -- Update
DJ
01/23Drug Firms Bet Billions on Biotech -- WSJ
DJ
01/22Stocks hit record as senators reach deal to end shutdown
RE
01/22Big Drugmakers Pay Big Prices for Promising Biotechs
DJ
01/22Dealmaking drives European stocks as equity melt-up continues
RE
01/22Biotech M&A takes off as Sanofi and Celgene spend $20 billion
RE
01/22CELGENE : to Buy Juno Therapeutics for $9 Billion -- 2nd Update
DJ
01/22Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
01/22New drugs recast $10 billion haemophilia market as Sanofi swoops in
RE
01/22CELGENE : to Buy Juno Therapeutics for $9 Billion -- Update
DJ
01/22CELGENE : to Buy Juno Therapeutics For $9 Billion
DJ
01/22Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
01/22Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
01/22BIOVERATIV : Sanofi shares fall on $11.6 billion Bioverativ takeover
RE
01/22SANOFI : Nears Deal for Bioverativ -- WSJ
DJ
01/22SANOFI : to Acquire Bioverativ for $11.6 Billion
DJ
01/22Big Drugmakers Pay Big Prices for Promising Biotechs -- Update
DJ
01/22SANOFI SET TO BUY BIOVERATIV FOR MOR : Wsj
RE
01/22SANOFI : Nears Deal to Buy Hemophilia Drugmaker Bioverativ for More Than $11.5 B..
DJ
01/22SANOFI : Nears Deal to Buy Hemophilia Drugmaker Bioverativ for More Than $11.5 B..
DJ
01/17CELGENE : Conducts Deal Talks With Juno -- WSJ
DJ
01/16CELGENE : in Talks to Buy Juno Therapeutics -- Update
DJ
01/16CELGENE : in Talks to Buy Juno Therapeutics
DJ
01/12Drugmakers see a pricing blueprint in an $850,000 gene therapy
RE
01/12SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
RE
01/08$11 billion biotech binge fuels forecasts of 2018 M&A surge
RE
01/08SANOFI : and Regeneron boost investment in cancer drug cemiplimab
RE
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
DJ
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
DJ
01/05Best week since April for European shares as UK, Swiss indexes hit records
RE
01/02New drug approvals hit 21-year high in 2017
RE
2017U.S. tax cuts mix pleasure and pain for Europe's dollar earners
RE
2017STOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
DJ
2017ALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
DJ
2017France's Sanofi pins hopes on new drugs after setbacks
RE
2017Sanofi investors hungry for drug progress and deal news
RE
Financials ($)
Sales 2017 1,58 M
EBIT 2017 -121 M
Net income 2017 -89,8 M
Finance 2017 23,9 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 348x
EV / Sales 2018 160x
Capitalization 572 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
PURETECH HEALTH PLC13.33%572
CELLTRION, INC.--.--%34 966
IQVIA HOLDINGS INC1.90%20 749
LONZA GROUP-6.95%19 587
INCYTE CORPORATION-10.56%17 877
NEKTAR THERAPEUTICS44.76%13 613
ALNYLAM PHARMACEUTICALS, INC.-6.19%11 719
ALKERMES PLC3.33%9 717
QIAGEN9.73%7 834
SEATTLE GENETICS, INC.1.14%7 788
SAGE THERAPEUTICS INC-0.52%6 727
IONIS PHARMACEUTICALS INC-0.87%6 222
ICON PLC-0.24%6 046
GALAPAGOS19.35%5 930
PRA HEALTH SCIENCES INC-2.28%5 639
EXACT SCIENCES CORPORATION-11.23%5 387
UNITED THERAPEUTICS CORPORATION-17.42%5 279
BIO-TECHNE CORP7.72%5 228
CHARLES RIVER LABORATORIES INTL. INC-2.17%5 078
FIBROGEN INC18.14%4 603
BB BIOTECH AG8.91%4 170